ERBB2 and neoplasm: Therefore, the study could not ascertain the effect of tumour size on the prognosis of patients either receiving more recent combination treatments (e.g. doxorubicin and/or taxane based and HER2 targeting treatments) or adjuvant hormone treatments or a combination of both.